Form 4: scPharmaceuticals CEO John H. Tucker Acquires 56,025 Shares Through Option Vesting

scPharmaceuticals CEO John H. Tucker reports the vesting of options for 56,025 shares of common stock following the achievement of performance conditions.

Summary

• On March 29, 2024, scPharmaceuticals CEO John H. Tucker acquired 56,025 shares of common stock through the vesting of stock options.
• These options were part of a grant of 112,050 options from January 25, 2021, which were subject to performance conditions.
• The Issuer's Board of Directors determined that the performance conditions for half of the grant (56,025 shares) were met.
• The remaining 56,025 options were previously forfeited due to the failure to meet certain performance conditions.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard executive compensation event. The vesting suggests some performance goals were met, but the forfeiture of other options tempers the positive aspect.

Positives

• The vesting of options indicates that certain performance goals were achieved by the company, as determined by the Board of Directors.

Negatives

• Half of the originally granted options were forfeited, suggesting that some performance goals were not met.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in publicly traded companies. It provides transparency into the equity-based compensation of key executives.

Stakeholder Impact

• The vesting of options aligns management's interests with those of shareholders, as it incentivizes executives to improve company performance.

Key Dates